Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
Davide MatinoFederico GerminiAnthony K C ChanKay DeckerEmma IsermanPierre ChelleAndrea N EdgintonOlayide OladoyinboElisabetta TrinariArun KeepanasserilAlfonso IorioPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2024)
This study provides routine clinical evidence supporting the benefits of switching from octocog alfa to damoctocog alfa pegol for patients with severe haemophilia A.